In 2010, scientists discovered that African Americans who are born with certain variants of a gene called apolipoprotein L1 (APOL1) have a higher-than-average risk for experiencing chronic kidney disease (CKD). Now, in a new study of African Americans with hypertension, researchers at the Icahn School of Medicine at Mount Sinai find that a community-based approach to reporting APOL1 genetic test results back to individuals may have beneficial effects.
Could a community-based approach to genetic testing help African Americans reduce risks of chronic kidney disease?
In 2010, scientists discovered that African Americans who are born with certain variants of a gene called apolipoprotein L1 (APOL1) have a higher-than-average risk for experiencing chronic kidney disease (CKD). Now, in a new study of African Americans with hypertension, researchers at the Icahn School of Medicine at Mount Sinai find that a community-based approach to reporting APOL1 genetic test results back to individuals may have beneficial effects.